Shilpa Medicare is currently trading at Rs. 498.70, up by 13.90 points or 2.87% from its previous closing of Rs. 484.80 on the BSE.
The scrip opened at Rs. 490.15 and has touched a high and low of Rs. 515.00 and Rs. 490.15 respectively. So far 11,097 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 623.35 on 05-Aug-2015 and a 52 week low of Rs. 355.00 on 20-Jan-2016.
Last one week high and low of the scrip stood at Rs. 515.00 and Rs. 442.00 respectively. The current market cap of the company is Rs. 3,669.00 crore.
The promoters holding in the company stood at 53.05%, while Institutions and Non-Institutions held 14.83% and 32.12% respectively.
Shilpa Medicare has received an approval for amalgamation of Navya Biologicals (NBPL) with itself. The merger is however subject to the approval/observation letters of requisite statutory bodies/ intermediaries including Stock Exchanges, shareholders and High Court of Karnataka/ National Company Law Tribunal and will be completed in 7 to 8 months.
The board of directors at their meeting held on June 27, 2016 has considered and approved for the same based on the recommendations of Audit Committee. The company’s board has approved the acquisition of NBPL in exchange for 14 lakh shares of company to be issued to the shareholders of NBPL.
NBPL is a company incorporated under the Companies Act, engaged in research and development activities in the field of biologicals. NBPL has specifically been in the development of bio-similars and bioprocess technology platforms.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1778.00 |
| Dr. Reddys Lab | 1210.60 |
| Cipla | 1487.45 |
| Lupin | 2058.85 |
| Zydus Lifesciences | 946.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
